pyridoxine hydrochloride - Resultados da pesquisa

pyridoxine hydrochloride injection, usp solution

mylan pharmaceuticals ulc - pyridoxine hydrochloride - solution - 100mg - pyridoxine hydrochloride 100mg - vitamin b complex

Canadá - inglês - Health Canada

pyridoxine hydrochloride injection usp 100 mg/ml solution

alveda pharmaceuticals inc - pyridoxine hydrochloride - solution - 100mg - pyridoxine hydrochloride 100mg - vitamin b complex

Estados Unidos - inglês - NLM (National Library of Medicine)

doxylamine succinate and pyridoxine hydrochloride tablet, delayed release

bryant ranch prepack - doxylamine succinate (unii: v9bi9b5yi2) (doxylamine - unii:95qb77jkpl), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z) - doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. limitations of use doxylamine succinate and pyridoxine hydrochloride delayed-release tablets have not been studied in women with hyperemesis gravidarum. doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are contraindicated in women with any of the following conditions: - known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation - monoamine oxidase (mao) inhibitors intensify and prolong the adverse central nervous system effects of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets [see drug interactions (7.1)] . risk summary doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are intended for the treatment of nausea and vomiting of pregnancy

Estados Unidos - inglês - NLM (National Library of Medicine)

doxylamine succinate and pyridoxine hydrochloride- doxylamine succinate and pyridoxine hydrochloride, delayed release tablets 10

bryant ranch prepack - doxylamine succinate (unii: v9bi9b5yi2) (doxylamine - unii:95qb77jkpl), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z) - doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. limitations of use doxylamine succinate and pyridoxine hydrochloride delayed-release tablet has not been studied in women with hyperemesis gravidarum. doxylamine succinate and pyridoxine hydrochloride is contraindicated in women with any of the following conditions: - known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation monoamine oxidase (mao) inhibitors intensify and prolong the adverse central nervous system effects of doxylamine succinate and pyridoxine hydrochloride [see drug interactions (7.1)]. risk summary doxylamine succinate and pyridoxine hydrochloride is intended for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. maternal risks a

Estados Unidos - inglês - NLM (National Library of Medicine)

diclegis- doxylamine succinate and pyridoxine hydrochloride tablet, delayed release

duchesnay usa, inc. - doxylamine succinate (unii: v9bi9b5yi2) (doxylamine - unii:95qb77jkpl), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z) - doxylamine succinate 10 mg - diclegis is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. limitations of use diclegis has not been studied in women with hyperemesis gravidarum. diclegis is contraindicated in women with any of the following conditions: risk summary diclegis is intended for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. maternal risks are discussed throughout the labeling. no increased risk for congenital malformations has been reported in epidemiologic studies in pregnant women. in the u.s. general population, the estimated background risks for major birth defects and miscarriage in clinically recognized pregnancies are 2-4% and 15-20%, respectively. data human data the combination of doxylamine succinate and pyridoxine hydrochloride has been the subject of many epidemiological studies (cohort, case control and meta-analyses) designed to detect possible teratogenicity. a meta-analysis of 16 coh